---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-303115"
form_type: "8-K"
ticker: "QTTB"
cik: "0001661998"
company_name: "Q32 Bio Inc."
filed_at: "2025-12-01T23:59:59+00:00"
generated_at: "2026-05-16T15:53:38.599406+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Q32 Bio sells complement inhibitor ADX-097 to Akebia for up to $592M total consideration

## Summary
- Upfront and guaranteed near-term payments of $12M ($7M at closing, $3M at 6 months, $2M milestone).
- Eligible for up to $92.5M in development/regulatory milestones and $487.5M commercial milestones.
- Tiered royalties on future sales of ADX-097 from low single-digit to mid-teen percent.
- Cash runway extended into H2 2027; topline SIGNAL-AA Part B data expected mid-2026.
- Q32 retains tissue-targeted complement platform including ADX-096; evaluating strategic options.

## SEC filing metadata
- accession: 0001193125-25-303115
- form_type: 8-K
- ticker: QTTB
- cik: 0001661998
- company_name: Q32 Bio Inc.
- filed_at: 2025-12-01T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 1.02, 2.01, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1661998/000119312525303115/0001193125-25-303115-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1661998/000119312525303115/d70163d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-303115
- JSON: https://secwatch.observer/filing/0001193125-25-303115.json
- Plain text: https://secwatch.observer/filing/0001193125-25-303115.txt

## Source-grounded claims
- claim_id: 96d4d89f439239fec2454586078f69dc21df07f6
  claim: Q32 Bio Inc. completed a disposition involving Akebia Therapeutics, Inc. for $7.0 million upfront (closed 2025-11-28).
  evidence_excerpt: will be responsible for any future development and commercialization of ADX-097. As consideration for the ADX-097 Asset Sale, the Company (i) received an upfront payment of $7.0 million on the Closing Date, and (ii) will receive a payment of $3.0 million on the six-month anniversary of the Closing Date. The Company will also receive a near-term milestone payment
  evidence_url: https://www.sec.gov/Archives/edgar/data/1661998/000119312525303115/0001193125-25-303115-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.